Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · September 28, 2019

Efficacy and Safety of Once-Weekly Semaglutide vs Daily Canagliflozin as Add-On to Metformin in Type 2 Diabetes

The Lancet Diabetes & Endocrinology

 

Additional Info

The Lancet Diabetes & Endocrinology
Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8): A Double-Blind, Phase 3b, Randomised Controlled Trial
Lancet Diabetes Endocrinol 2019 Sep 17;[EPub Ahead of Print], I Lingvay, AM Catarig, JP Frias, H Kumar, NL Lausvig, CW le Roux, D Thielke, A Viljoen, RJ McCrimmon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading